SLNO
Soleno Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.19 / 10
Outperform
Analyst consensus is Strong Buy/Buy (50% each) from two analysts with decent historical win rates. Fund-flow score 7.83 is good, but overall trend negative; small and large flows positive, medium and extra-large negative. Fraud investigation news introduces uncertainty. The positive analyst view is not yet confirmed by fund inflows.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-20
InstitutionWells Fargo
Times predicted3
Historical Win Rate66.7%
Is money flowing into or out of SLNO?
- SLNO holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.19/10 (Outperform).
